EcoDrugPlus

Janus Kinase 2b

Ensembl ID : ENSSLUG00000010126
Gene Symbol: JAK2B
1 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSSLUG00000014388
Gene Symbol: KITB
1 Cross references
200 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSLUG00000018406
Gene Symbol: LYN
1 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSSLUG00000021095
Gene Symbol: LOC116062189
3 Cross references
174 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSSLUG00000005856
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSSLUG00000022633
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSSLUG00000007099
Gene Symbol: MKNK2
3 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSSLUG00000006642
Gene Symbol: MCL1B
1 Cross references
170 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSSLUG00000008233
Gene Symbol: MDM2
3 Cross references
275 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSSLUG00000016694
Gene Symbol: MET
1 Cross references
205 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSSLUG00000013523
Gene Symbol: MLST8
3 Cross references
198 Possible Orthologues:

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSSLUG00000008999
Gene Symbol: NQO1
1 Cross references
153 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).